Ianalumab's Success in Phase III Trials Marks a Turning Point in Sjögren's Disease

(MedPage Today) -- In the recently reported NEPTUNUS-1 and -2 trials, presented at this year's American College of Rheumatology (ACR) annual meeting, investigators found that the anti-B-cell activating factor receptor (BAFF-R) antibody ianalumab...